(lp0
S"Alimera Sciences, Inc.  Looks Good: Stock Up 12.8% Yahoo Finance - Mar 14, 2017 Alimera Sciences, Inc. ALIM was a big mover last session, as the company saw its shares rise almost 13% on the day. The upside was driven by the company's improved fourth-quarter and full-year 2016 results."
p1
aS'Alimera Sciences: 2017 Outlook Seeking Alpha - Feb 10, 2017 Alimera had a big sequential jump in net sales in Q2 followed by a dip in Q3. The company explained on the Q3 call that Q2 sales were inflated by a distributor inventory buildup and that end-user demand was actually slightly higher in Q3 compared to Q2.'
p2
aS'ALIMERA SCIENCES, INC.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 1, 2017 Alimera Sciences, Inc.  is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial ... - GlobeNewswire Alimera Sciences Inc  Issues Quarterly Earnings Results, Misses ... - Chaffey Breeze'
p3
aS'News Alimera Sciences Inc.ALIM Wall Street Journal - Feb 11, 2011 News Alimera Sciences Inc.ALIM. Significant News Only. 03/07/17; Press Release. Alimera Sciences to Present at the 29th Annual ROTH Conference.'
p4
aS'Eye drug company Alimera Sciences mulls sale: sources Reuters - Dec 17, 2015 Alimera Sciences Inc, an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter.Alimera Sciences Inc  Stock is Up Amid Reaching Distribution Drug Deal ... - Independent Reporter'
p5
aS'Alimera Sciences and Knight Therapeutics Announce Filing of New Drug ... Yahoo Finance - Feb 22, 2017 ATLANTA, GEORGIA and MONTREAL, QUEBEC-- - Alimera Sciences, Inc.  , a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, and Knight Therapeutics Inc.Healthcare Volatile Stocks: Alimera Sciences, Inc. , Ocular ... - Seneca GlobeWhat do Analysts Say about: Alimera Sciences, Inc.  - News Oracle'
p6
aS'Alimera Sciences: Insiders Buying This Biotech, Stock Sees Catalyst Seeking Alpha - Oct 12, 2015 Alimera Sciences  is a bio-pharmaceutical company on the Nasdaq with a market cap of $116 million. The company has developed a product called Iluvien, which was FDA approved in 2014 and made commercially available in the US, UK,&nbsp;...'
p7
aS"Alimera: Risks Reduced After Q2 Pre-Announcement Seeking Alpha - Jul 28, 2016 The company's market cap before today's jump was just around $50 million, which is very low considering Iluvien's potential."
p8
aS'Alimera up 10% on ILUVIEN regulatory filing in Canada Seeking Alpha - Feb 22, 2017 Thinly traded nano cap Alimera Sciences  perks up on almost a 7x surge in volume in response to the news that distribution partner Knight Therapeutics has filed a New Drug Submission in Canada seeking approval of ILUVIEN (fluocinolone&nbsp;...'
p9
aS'Alimera Sciences Inc Risk Points versus Health Care CML News - Feb 14, 2017 This is a scatter plot analysis of the critical risk points from the option market for Alimera Sciences Inc  compared to its own past and the Health Care ETF.'
p10
a.